Noninvasive Prenatal Testing Market Set for Explosive Growth
|
By HospiMedica International staff writers Posted on 21 Jan 2014 |
|
The global noninvasive prenatal testing (NIPT) market is expected to grow more than ten-fold in the next five years. These are the latest findings of Transparency Market Research (Albany, NY, USA), a global information and research provider.
NIPT, the noninvasive genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.) can detect the presence of abnormalities in fetuses of pregnant women as early as 9–10 weeks of gestation, with some of the most commonly detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X. The market is also evolving rapidly due the advantages it offers over conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS). These advantages include safety, accuracy, and no risk of miscarriage.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest, and BambniTest are currently the commercially available NIPTs, all based on the direct analysis of cell-free fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of Sequenom) accounted for the largest share (36.6%) of the market in terms of revenue, owing to the fact that it was the first mover in the market place. During the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing market penetration by other, aforementioned NIPTs such as Panorama and verify.
Almost every company in this market is adopting the same business model of marketing their tests via alliances with hospitals, diagnostic laboratories, and physician offices. The increasing penetration by test developers in European, Asia-Pacific, and Middle East countries indicates promising growth in the near future. Sequenom (San Diego, CA, USA), Verinata Health (Redwood City, CA, USA), Ariosa Diagnostics, and Natera (San Carols, CA, USA), are the leading companies engaged in providing noninvasive prenatal tests worldwide.
The global NIPT market was valued at USD 220 million in 2012 and is expected to grow at a compound annual growth rate (CAGR) of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion by 2019. Geographically, North America was the largest regional market in 2012, with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Related Links:
Transparency Market Research
Sequenom
Verinata Health
NIPT, the noninvasive genetic screening test for common chromosomal abnormalities (trisomy 21, trisomy 18, trisomy 13, monosomy X, etc.) can detect the presence of abnormalities in fetuses of pregnant women as early as 9–10 weeks of gestation, with some of the most commonly detected chromosomal aneuploidies include Down syndrome, Edwards syndrome, Patau syndrome, and monosomy X. The market is also evolving rapidly due the advantages it offers over conventional prenatal screening and diagnostic methods such as maternal serum screening, nuchal translucency (NT) scan, amniocentesis, and chorionic villus sampling (CVS). These advantages include safety, accuracy, and no risk of miscarriage.
MaterniT21 PLUS, verifi, Harmony, Panorama, NIFTY, PrenaTest, and BambniTest are currently the commercially available NIPTs, all based on the direct analysis of cell-free fetal DNA in the maternal blood. In 2012, MaterniT21 (a proprietary product of Sequenom) accounted for the largest share (36.6%) of the market in terms of revenue, owing to the fact that it was the first mover in the market place. During the forecast period 2013 to 2019, it is likely to lose some of its share due to increasing market penetration by other, aforementioned NIPTs such as Panorama and verify.
Almost every company in this market is adopting the same business model of marketing their tests via alliances with hospitals, diagnostic laboratories, and physician offices. The increasing penetration by test developers in European, Asia-Pacific, and Middle East countries indicates promising growth in the near future. Sequenom (San Diego, CA, USA), Verinata Health (Redwood City, CA, USA), Ariosa Diagnostics, and Natera (San Carols, CA, USA), are the leading companies engaged in providing noninvasive prenatal tests worldwide.
The global NIPT market was valued at USD 220 million in 2012 and is expected to grow at a compound annual growth rate (CAGR) of 37.6% from 2013 to 2019, to reach an estimated value of USD 3.62 billion by 2019. Geographically, North America was the largest regional market in 2012, with a market share of 64.5% of the total revenue generated globally, followed by Europe.
Related Links:
Transparency Market Research
Sequenom
Verinata Health
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Syringe Pump
SP50 Series
Gas Analyzer
GE SAM
Latest Business News
- World Health Expo to Showcase Trillion-Dollar Growth Across Pharma, Biotech, Longevity and Wellness at 2027 Edition
- Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery
- Robotic Single-Port System Gains CE Mark for Transvaginal Gynecologic Procedures
- Smartphone-Integrated Epinephrine Auto-Injector Concept Wins Red Dot Design Award
- Partnership Advances AI Tool for Predicting Malignant Cerebral Edema
- First U.S. Commercial Cases Demonstrate New Approach to Transseptal Access
- Philips and Imricor Collaboration Advances MRI-Guided Cardiac Procedures
- FDA Approval Clears Path for BCI Integration with Personal Computing Devices
- Abbott LAA Occluder Gains CE Mark for AFib Stroke Risk Reduction
- Smart Hospital Market Set for Strong Growth as Digital Healthcare Adoption Accelerates
- FDA Seeks Feedback on Regulating Generative AI Medical Devices
- Teledyne to Acquire Varex Imaging in $1.1 Billion Deal
- MIMEDX to Add Sanara MedTech’s Regenerative Technologies Through $350 Million Deal
- AI Software Combines Nodule Detection and Diagnosis for Lung Cancer Screening
- AI Care Platform Adds Quantitative MRI Analysis for Multiple Sclerosis
- Danaher Completes Acquisition of Masimo to Expand Patient Monitoring Capabilities
Channels
Artificial Intelligence
view channel
AI Model Predicts Prolonged Sitting in Chronic Pelvic Pain
Chronic pelvic pain affects an estimated one in seven women and can occur with conditions such as endometriosis, adenomyosis, or uterine fibroids. Pain, fatigue, and other symptoms may contribute to prolonged... Read more
Autonomous AI Helps Streamline Urgent Skin Cancer Referrals
Urgent suspected skin cancer referrals place substantial pressure on dermatology services. In England, referrals have almost tripled since 2009, yet only about 6% lead to an urgent skin cancer diagnosis.... Read more
Critical Care
view channel
Minimally Invasive Ultrasound-Guided Procedure Eases Carpal Tunnel Symptoms
Carpal tunnel syndrome occurs when the median nerve is compressed within the wrist, causing numbness, tingling, weakness, and pain. The condition is linked to repetitive wrist and hand motion and affects... Read more
Standardized Scoring Tool Supports ICU Discharge Decisions
Intensive care unit (ICU) discharge requires clinicians to determine whether a critically ill patient can safely transfer to a lower-acuity unit. When patients deteriorate soon after transfer, “bounce-back”... Read more
Surgical Techniques
view channel
New FDA-Approved Pediatric Pulmonary Valve Can Expand as Children Grow
Congenital pulmonary valve disease affects the valve that directs blood from the heart to the lungs. Even after repair, some children develop valve leakage that can strain and enlarge the right side of the heart.... Read more
PSMA PET/CT Imaging Guides Treatment Selection in Recurrent Prostate Cancer
Prostate cancer can return after surgery, sometimes appearing in different locations over time. A rising prostate-specific antigen (PSA) level may be the first sign of recurrence, while microscopic disease... Read more
Patient Care
view channel
At-Home Neuromodulation Shows Promise in Selected Patients With Hypertension
High blood pressure is a major risk factor for cardiovascular disease, including heart attack and stroke. Many patients receiving treatment for hypertension still remain above recommended blood pressure... Read more
EHR Model Flags High-Risk Periods in Patients with Metastatic Breast Cancer
Determining when patients with metastatic breast cancer are nearing the end of life remains difficult, often leading to intensive interventions with limited benefit. Prognostic uncertainty can delay goals-of-care... Read more
Medical Imaging
view channel
AI Software Detects Osteoporosis from Routine CT Scans
Osteoporosis can progress for years without pain, leaving bone loss undetected until a fracture or back pain prompts testing. By that point, bone loss may already be advanced. Bone density testing is not... Read more
AI Model Uses Pretreatment CT Scans to Predict Immunotherapy-Related Pneumonitis Risk
Pneumonitis is a potentially life-threatening form of lung inflammation that affects about 10% of patients with lung cancer receiving immunotherapy. Because it can be difficult to predict before symptoms... Read more
Health IT
view channel
Adaptive Radiation QA Software Gains Validation for NeoArc Treatments
Adaptive radiation therapy allows clinicians to adjust treatment plans to daily anatomical changes such as tumor shrinkage, weight loss, or organ movement, improving precision while limiting exposure to... Read more
Healthcare Database Helps Close Long COVID Surveillance Gap
Long COVID is a chronic condition that occurs after SARS-CoV-2 infection and lasts at least three months. It can follow severe illness, but it can also affect anyone who has been infected.... Read more
Point of Care
view channel
Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes
Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more
